论文部分内容阅读
CD317(Tetherin,BST-2或HM1.24)于1994年被发现并命名,是终末分化B细胞的特异性表面标志。2008年首次被鉴定为干扰素诱导型宿主抗病毒因子,此后越来越多的科学家加入到该领域的探索中。经过近十年的研究,目前已经阐述了CD317结构、抗病毒及免疫特性等问题,也陆续发现了一些诸如参与肿瘤进展、束缚外泌体释放等新功能,研究热度不减当年。因此,文章对近几年CD317功能的研究进展进行一个系统的总结,以期为病毒感染、肿瘤发病以及治疗等方面的理论进步和技术发展提供新的思路。
CD317 (Tetherin, BST-2 or HM1.24) was discovered in 1994 and named, is a specific surface marker of terminally differentiated B cells. It was first identified as an IFN-inducible host anti-viral factor in 2008, and more and more scientists have since joined the field to explore. After nearly ten years of research, we have now described the structure of CD317, anti-virus and immune characteristics and other issues, but also gradually found some new features such as participation in tumor progression, the release of bound exosomes, research unabated that year. Therefore, the article summarizes the research progress of CD317 function in recent years, with a view to providing new ideas for the theoretical progress and technological development in virus infection, tumor onset and treatment.